绝经后会发生什么?(WHAM):降低风险输卵管卵巢切除术对24个月时抑郁和焦虑症状的影响
前瞻性对照研究纳入59例计划行降低风险输卵管卵巢切除术(RRSO)的绝经前女性和91例保留卵巢的对照,测量基线、12和24个月时抑郁(CESD)和焦虑(GAD-7)症状。24个月时抑郁和焦虑症状未高于基线,RRSO组与对照组无差异(P > 0.05);12个月时抑郁症状(OR = 24,P < 0.001)和焦虑症状(OR = 13,P < 0.001)强烈预测24个月时相应症状;未观察到绝经激素治疗(MHT)使用与抑郁或焦虑症状的关联。
要点
- RRSO后24个月抑郁和焦虑症状未高于基线,与保留卵巢对照组无差异(P > 0.05)。
- 12个月时抑郁症状(OR = 24,P < 0.001)和焦虑症状(OR = 13,P < 0.001)强烈预测24个月时相应症状。
- 未观察到MHT使用与抑郁或焦虑症状的关联。
核心结论
- RRSO后24个月抑郁和焦虑症状未升高,但RRSO后12个月时的抑郁症状可能在24个月时持续存在。
研究设计与样本
- 前瞻性对照研究,纳入59例计划行RRSO的绝经前女性和91例保留卵巢的对照。
- 在基线(RRSO前)、12和24个月测量抑郁(CESD)和焦虑(GAD-7)症状。
- 使用普通和逻辑多变量回归估计24个月时组间和组内差异,并在调整基线和12个月测量前后进行分析。
主要发现
- 24个月时,抑郁和焦虑症状总体未高于基线,RRSO组与对照组无差异(P > 0.05),调整既往测量前后均如此。
- 12个月时抑郁症状升高(OR = 24,P < 0.001)和12个月时焦虑症状升高(OR = 13,P < 0.001)强烈预测24个月时相应测量。
- 考虑12个月症状后,基线抑郁症状升高不再预测24个月症状,但基线焦虑症状升高仍预测24个月焦虑,即使考虑12个月焦虑时。
- 未观察到MHT使用与抑郁或焦虑症状之间的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For women with pathogenic variants in BRCA1 and BRCA2, risk-reducing salpingo-oophorectomy (RRSO) at the recommended age causes surgical menopause. We previously reported elevated depressive symptoms at 6 and 12 months and elevated anxiety symptoms at 6 months after RRSO. We now report these outcomes at 24 months, their baseline and 12-month predictors and the effect of Menopausal Hormone Therapy (MHT). METHODS: Prospective controlled study of 59 premenopausal women planning RRSO and 91 comparisons who retained their ovaries. Depressive (CESD) and anxiety symptoms (GAD-7) were measured at baseline (before RRSO) and at 12 and 24 months. We used ordinary and logistic multivariable regression to estimate differences between and within groups at 24 months, before and after conditioning on baseline and 12 month measures. RESULTS: Overall, depressive and anxiety symptoms were not elevated above baseline at 24 months and did not differ between RRSO and comparisons, before or after adjusting for previous measures (P > 0.05). Elevated depressive symptoms at 12 months (OR = 24, P < 0.001), and elevated anxiety symptoms at 12 months (OR = 13, P < 0.001), strongly predicted 24 month measures. Elevated depressive symptoms at baseline no longer predicted 24 month symptoms once 12 month symptoms were considered, but elevated baseline anxiety still predicted anxiety at 24 months, even when 12 month anxiety was considered. No association between MHT use and depressive or anxiety symptoms was observed. CONCLUSIONS: Depressive and anxiety symptoms are not elevated 24 months after RRSO. However, depressive symptoms at 12 months after RRSO are likely to persist at 24 months.
引用
- Hickey M, Nguyen TL, Krejany EO, et al. What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months. Gynecol Oncol. 2024. PMID: 39504590. doi:10.1016/j.ygyno.2024.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。